Insiders · EBS

Keith Katkin

Director at Emergent BioSolutions Inc. (EBS) since April 2022

Keith Katkin has filed 23 insider reports with the SEC since February 2021, as director at Emergent BioSolutions Inc. (EBS), director at Syndax Pharmaceuticals Inc (SNDX) and director at Eledon Pharmaceuticals, Inc. (ELDN). In the last 12 months Keith Katkin sold $128K of stock on the open market. In the latest filing, on May 4, 2026, Keith Katkin sold 15,481 shares of Emergent BioSolutions Inc. (EBS) for $128K at an average of $8.28.

Filings
23
Companies
3
Bought on market
$91.1K
Sold on market
$1.05M

Companies where Keith Katkin is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Emergent BioSolutions Inc. logo
EBS
Emergent BioSolutions Inc.
Directorsince April 202296,294$178K$5.05May 4, 2026
Syndax Pharmaceuticals Inc logo
SNDX
Syndax Pharmaceuticals Inc
Director124,000$91.1K$877K$9.11$8.72-4.3%Feb 6, 2026
Eledon Pharmaceuticals, Inc. logo
ELDN
Eledon Pharmaceuticals, Inc.
Director8,575$1.78Jan 16, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record. Price now: the latest daily close, against the average buy price.

Every filing

Compare Keith Katkin with

Other insiders at the same companies

Questions about Keith Katkin

What is Keith Katkin's role at Emergent BioSolutions Inc.?
Keith Katkin reports to the SEC as director at Emergent BioSolutions Inc. (EBS), according to the latest filing on May 4, 2026. Keith Katkin has also filed as director at Syndax Pharmaceuticals Inc (SNDX) and director at Eledon Pharmaceuticals, Inc. (ELDN).
How many shares does Keith Katkin own?
After the latest filing that states it, Keith Katkin directly owned 96,294 shares of Emergent BioSolutions Inc. (EBS), 124,000 shares of Syndax Pharmaceuticals Inc (SNDX) and 8,575 shares of Eledon Pharmaceuticals, Inc. (ELDN). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Keith Katkin bought or sold stock recently?
The most recent open-market purchase was on May 19, 2025: bought 10,000 shares of Syndax Pharmaceuticals Inc (SNDX) for $91.1K at an average of $9.11. The most recent open-market sale was on April 30, 2026: sold 15,481 shares of Emergent BioSolutions Inc. (EBS) for $128K at an average of $8.28.
How do I get alerts when Keith Katkin files?
Follow Keith Katkin on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Keith Katkin (SEC CIK 0001314596). Totals count each trade once, skipping amendments whose original is on file, from Feb 5, 2021 on. View on SEC EDGAR · Get this as JSON